National Jewish Medical and Research Center discharged Robert Daniels, the multi-drug-resistant tuberculosis patient who came to the center from Arizona, today at 11 a.m. Daniels was scheduled to take a commercial airplane flight back to Phoenix this afternoon escorted by a private security guard hired by Maricopa County Public Health Department in Arizona.
Beijing registered 563 new cases of HIV/AIDS in the first half of this year, up 50 per cent from the same period last year, mostly through needle sharing and sex, a health official said here.
Tibotec Pharmaceuticals Ltd. announced that the New Drug Application (NDA) for TMC125 (etravirine), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), has been accepted for priority review by the United States Food and Drug Administration (FDA).
The Indian government plans to establish a laboratory network to increase the detection of multi-drug resistant tuberculosis cases nationwide.
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced publication of a study by Sirtris and Harvard University scientists in the journal Cell that reveals a new mechanism to slow aging.
The U.S. Food and Drug Administration (FDA) sent a warning letter to Procter & Gamble for making unlawful claims about its Vicks Early Defense Foaming Hand Sanitizer (Early Defense) product.
Based in part on NIGMS-supported research on how gene variation affects a person’s response to medicines, the U.S. Food and Drug Administration has modified the prescribing instructions for warfarin (Coumadin), a widely used blood thinner.
In the year since it was established to provide medicines for HIV/AIDS, malaria and tuberculosis to the poorest people of developing countries, the United Nations-backed international drug purchase facility UNITAID has managed to reduce the price of HIV treatments for children by almost 40 per cent.
In an 18-year-study on attention-deficit/hyperactivity disorder (AD/HD), Mayo Clinic researchers found that treatment with prescription stimulants is associated with improved long-term academic success of children with AD/HD.
The North Central Cancer Treatment Group (NCCTG), a clinical research group based at Mayo Clinic, has received a $34.4 million renewal grant from the National Cancer Institute (NCI). The grant, to be awarded over a six-year period, will help fund NCCTG’s efforts to develop and conduct clinical trials to test new cancer therapies.